The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients

Stefano Molica, Tait D. Shanafelt, Diana Giannarelli, Massimo Gentile, Rosanna Mirabelli, Giovanna Cutrona, Luciano Levato, Nicola Di Renzo, Francesco Di Raimondo, Caterina Musolino, Francesco Angrilli, Angelo Famà, Anna Grazia Recchia, Kari G. Chaffee, Antonino Neri, Neil Elliot Kay, Manlio Ferrarini, Fortunato Morabito

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and ≥ 2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (P < 0.0001.; C-statistic:c = 0.72; 95% CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090–1095, 2016.

Original languageEnglish (US)
Pages (from-to)1090-1095
Number of pages6
JournalAmerican Journal of Hematology
Volume91
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Survival
Observational Studies
Mutation
Serum

Keywords

  • leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL : Independent validation in a prospective cohort of early stage patients. / Molica, Stefano; Shanafelt, Tait D.; Giannarelli, Diana; Gentile, Massimo; Mirabelli, Rosanna; Cutrona, Giovanna; Levato, Luciano; Di Renzo, Nicola; Di Raimondo, Francesco; Musolino, Caterina; Angrilli, Francesco; Famà, Angelo; Recchia, Anna Grazia; Chaffee, Kari G.; Neri, Antonino; Kay, Neil Elliot; Ferrarini, Manlio; Morabito, Fortunato.

In: American Journal of Hematology, Vol. 91, No. 11, 01.11.2016, p. 1090-1095.

Research output: Contribution to journalArticle

Molica, S, Shanafelt, TD, Giannarelli, D, Gentile, M, Mirabelli, R, Cutrona, G, Levato, L, Di Renzo, N, Di Raimondo, F, Musolino, C, Angrilli, F, Famà, A, Recchia, AG, Chaffee, KG, Neri, A, Kay, NE, Ferrarini, M & Morabito, F 2016, 'The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients', American Journal of Hematology, vol. 91, no. 11, pp. 1090-1095. https://doi.org/10.1002/ajh.24493
Molica, Stefano ; Shanafelt, Tait D. ; Giannarelli, Diana ; Gentile, Massimo ; Mirabelli, Rosanna ; Cutrona, Giovanna ; Levato, Luciano ; Di Renzo, Nicola ; Di Raimondo, Francesco ; Musolino, Caterina ; Angrilli, Francesco ; Famà, Angelo ; Recchia, Anna Grazia ; Chaffee, Kari G. ; Neri, Antonino ; Kay, Neil Elliot ; Ferrarini, Manlio ; Morabito, Fortunato. / The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL : Independent validation in a prospective cohort of early stage patients. In: American Journal of Hematology. 2016 ; Vol. 91, No. 11. pp. 1090-1095.
@article{13e2d044a2584ef7940e5cb4e5813ba2,
title = "The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients",
abstract = "The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and ≥ 2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85{\%}, 67{\%} and 46{\%} in these three categories (P < 0.0001.; C-statistic:c = 0.72; 95{\%} CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090–1095, 2016.",
keywords = "leukemia",
author = "Stefano Molica and Shanafelt, {Tait D.} and Diana Giannarelli and Massimo Gentile and Rosanna Mirabelli and Giovanna Cutrona and Luciano Levato and {Di Renzo}, Nicola and {Di Raimondo}, Francesco and Caterina Musolino and Francesco Angrilli and Angelo Fam{\`a} and Recchia, {Anna Grazia} and Chaffee, {Kari G.} and Antonino Neri and Kay, {Neil Elliot} and Manlio Ferrarini and Fortunato Morabito",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/ajh.24493",
language = "English (US)",
volume = "91",
pages = "1090--1095",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL

T2 - Independent validation in a prospective cohort of early stage patients

AU - Molica, Stefano

AU - Shanafelt, Tait D.

AU - Giannarelli, Diana

AU - Gentile, Massimo

AU - Mirabelli, Rosanna

AU - Cutrona, Giovanna

AU - Levato, Luciano

AU - Di Renzo, Nicola

AU - Di Raimondo, Francesco

AU - Musolino, Caterina

AU - Angrilli, Francesco

AU - Famà, Angelo

AU - Recchia, Anna Grazia

AU - Chaffee, Kari G.

AU - Neri, Antonino

AU - Kay, Neil Elliot

AU - Ferrarini, Manlio

AU - Morabito, Fortunato

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and ≥ 2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (P < 0.0001.; C-statistic:c = 0.72; 95% CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090–1095, 2016.

AB - The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and ≥ 2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (P < 0.0001.; C-statistic:c = 0.72; 95% CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090–1095, 2016.

KW - leukemia

UR - http://www.scopus.com/inward/record.url?scp=84991787701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991787701&partnerID=8YFLogxK

U2 - 10.1002/ajh.24493

DO - 10.1002/ajh.24493

M3 - Article

C2 - 27465919

AN - SCOPUS:84991787701

VL - 91

SP - 1090

EP - 1095

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -